Turnstone Biologics Stock Price, News & Analysis (NASDAQ:TSBX) $2.71 -0.28 (-9.36%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$2.61▼$3.0050-Day Range$1.80▼$3.9452-Week Range$1.63▼$13.20Volume132,293 shsAverage Volume88,430 shsMarket Capitalization$62.57 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Turnstone Biologics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside601.1% Upside$19.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.45) to ($3.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.55 out of 5 starsMedical Sector748th out of 949 stocksBiological Products, Except Diagnostic Industry119th out of 149 stocks 3.3 Analyst's Opinion Consensus RatingTurnstone Biologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.00, Turnstone Biologics has a forecasted upside of 601.1% from its current price of $2.71.Amount of Analyst CoverageTurnstone Biologics has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for TSBX. Previous Next 0.0 Dividend Strength Dividend YieldTurnstone Biologics does not currently pay a dividend.Dividend GrowthTurnstone Biologics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TSBX. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Turnstone Biologics this week, compared to 0 articles on an average week.Search Interest10 people have searched for TSBX on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Turnstone Biologics insiders have not sold or bought any company stock.Percentage Held by Institutions46.44% of the stock of Turnstone Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Turnstone Biologics are expected to grow in the coming year, from ($3.45) to ($3.06) per share. Previous Next See Top Rated MarketRank™ Stocks Here About Turnstone Biologics Stock (NASDAQ:TSBX)Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.Read More TSBX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TSBX Stock News HeadlinesDecember 1, 2023 | americanbankingnews.comCritical Contrast: Turnstone Biologics (NASDAQ:TSBX) & CEL-SCI (NYSE:CVM)November 27, 2023 | finance.yahoo.comTurnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare ConferenceDecember 5, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 27, 2023 | americanbankingnews.comTurnstone Biologics (NASDAQ:TSBX) & Poseida Therapeutics (NASDAQ:PSTX) Financial AnalysisNovember 19, 2023 | realmoney.thestreet.comTurnstone Biologics price target lowered to $15 from $18 at BofANovember 10, 2023 | msn.comTurnstone Biologics GAAP EPS of -$1.00November 10, 2023 | msn.comTurnstone Biologics GAAP EPS of $1.00November 9, 2023 | finance.yahoo.comTurnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business HighlightsDecember 5, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 5, 2023 | morningstar.comTurnstone Biologics Corp TSBXNovember 3, 2023 | finance.yahoo.comTurnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual MeetingSeptember 28, 2023 | finance.yahoo.comTurnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingSeptember 4, 2023 | msn.comTurnstone Biologics GAAP EPS of -$7.56 misses by $6.82September 1, 2023 | finance.yahoo.comTurnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 28, 2023 | wsj.comTurnstone Biologics Corp.July 25, 2023 | money.usnews.comTurnstone Biologics CorpJuly 24, 2023 | finance.yahoo.comTurnstone Biologics Corp. Announces Pricing of Upsized Initial Public OfferingJuly 24, 2023 | investing.comTurnstone Biologics Corp (TSBX)See More Headlines Receive TSBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Turnstone Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/05/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/08/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TSBX CUSIPN/A CIK1764974 Webturnstonebio.com Phone347-897-5988FaxN/AEmployees94Year FoundedN/APrice Target and Rating Average Stock Price Target$19.00 High Stock Price Target$20.00 Low Stock Price Target$18.00 Potential Upside/Downside+601.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,830,000.00 Net Margins-22.16% Pretax Margin-176.53% Return on EquityN/A Return on Assets-50.73% Debt Debt-to-Equity RatioN/A Current Ratio9.08 Quick Ratio9.08 Sales & Book Value Annual Sales$73.30 million Price / Sales0.85 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares23,090,000Free FloatN/AMarket Cap$62.57 million OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Sammy J. Farah M.B.A. (Age 51)Ph.D., President, CEO & Director Comp: $678.51kDr. Venkat Ramanan Ph.D. (Age 54)Chief Financial Officer Comp: $346.13kDr. Michael F. Burgess M.D. (Age 60)MBChB, Ph.D., Interim Chief Medical Officer & Executive Director Comp: $212.69kMs. Saryah Azmat (Age 34)Chief Business Officer Comp: $479.73kDr. Vijay Chiruvolu M.B.A. (Age 61)Ph.D., Interim Chief Technology Officer Dr. Stewart Abbot Ph.D. (Age 56)Chief Scientific Officer Mr. P. Joseph Campisi Jr. (Age 62)Esq., J.D., M.B.A., Chief Legal Officer More ExecutivesKey CompetitorsSAB BiotherapeuticsNASDAQ:SABSOKYO PharmaNASDAQ:OKYODyadic InternationalNASDAQ:DYAIAligos TherapeuticsNASDAQ:ALGSAthira PharmaNASDAQ:ATHAView All CompetitorsInsiders & InstitutionsSectoral Asset Management Inc.Bought 517,648 shares on 11/15/2023Ownership: 2.266%Eventide Asset Management LLCBought 708,317 shares on 11/14/2023Ownership: 3.101%FMR LLCBought 2,830,284 shares on 11/13/2023Ownership: 12.392%Northern Trust CorpBought 57,782 shares on 11/13/2023Ownership: 0.253%Citigroup Inc.Bought 7,524 shares on 11/9/2023Ownership: 0.033%View All Insider TransactionsView All Institutional Transactions TSBX Stock Analysis - Frequently Asked Questions Should I buy or sell Turnstone Biologics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turnstone Biologics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TSBX shares. View TSBX analyst ratings or view top-rated stocks. What is Turnstone Biologics' stock price target for 2024? 4 brokers have issued 1 year target prices for Turnstone Biologics' shares. Their TSBX share price targets range from $18.00 to $20.00. On average, they expect the company's share price to reach $19.00 in the next year. This suggests a possible upside of 601.1% from the stock's current price. View analysts price targets for TSBX or view top-rated stocks among Wall Street analysts. How have TSBX shares performed in 2023? Turnstone Biologics' stock was trading at $11.00 at the beginning of the year. Since then, TSBX stock has decreased by 75.4% and is now trading at $2.71. View the best growth stocks for 2023 here. When is Turnstone Biologics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024. View our TSBX earnings forecast. How were Turnstone Biologics' earnings last quarter? Turnstone Biologics Corp. (NASDAQ:TSBX) posted its quarterly earnings data on Thursday, November, 9th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.33. When did Turnstone Biologics IPO? (TSBX) raised $80 million in an IPO on Friday, July 21st 2023. The company issued 6,666,667 shares at a price of $12.00 per share. When does Turnstone Biologics' lock-up period expire? Turnstone Biologics' lock-up period expires on Wednesday, January 17th. Turnstone Biologics had issued 6,666,667 shares in its IPO on July 21st. The total size of the offering was $80,000,004 based on an initial share price of $12.00. After the expiration of Turnstone Biologics' lock-up period, company insiders and major shareholders will be able to sell their shares of the company. Who are Turnstone Biologics' major shareholders? Turnstone Biologics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (12.39%), Eventide Asset Management LLC (3.10%), Sectoral Asset Management Inc. (2.27%), Northern Trust Corp (0.25%), New York State Common Retirement Fund (0.08%) and Charles Schwab Investment Management Inc. (0.07%). Insiders that own company stock include Rishi Gupta and Versant Ventures V, Llc. View institutional ownership trends. How do I buy shares of Turnstone Biologics? Shares of TSBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:TSBX) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Turnstone Biologics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.